USP1 and plasma cell myeloma: Upregulation of USP1 is related to progression and poor prognosis such as, multiple myeloma (Das et al., 2017), and hepatocellular carcinoma (Zhao et al., 2020), and also mediated chemotherapy resistance (Sonego et al., 2019) (García-Santisteban et al., 2013).